Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tazarotene (Zorac) 是一种选择性视黄酸受体激动剂,用于研究寻常痤疮和斑块状银屑病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 257 | 现货 | ||
10 mg | ¥ 398 | 现货 | ||
25 mg | ¥ 723 | 现货 | ||
50 mg | ¥ 1,320 | 现货 | ||
100 mg | ¥ 1,960 | 现货 | ||
200 mg | ¥ 2,970 | 现货 | ||
500 mg | ¥ 4,830 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 397 | 现货 |
产品描述 | Tazarotene (Zorac) is a synthetic, topical retinoid. Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene. In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. |
体外活性 | Tazarotene causes ERK activation, RB tumor suppressor protein hypophosphorylation, G0 arrest, and myeloid differentiation in HL-60 human myeloblastic leukemia cells. Tazarotene could propel either early or late portions of the period leading to differentiation and G0 arrest and is interchangeable with an RARalpha-selective ligand. [1] Tazarotene therapy regulates gene transcription via interaction with specific nuclear retinoic acid receptors (RARs), thereby modulating the three key pathogenic factors in psoriasis. [2] Tazarotene inhibits the proliferation of fibroblasts and synthesis of DNA and collagen. [3] Tazarotene down-regulates markers of keratinocyte differentiation, keratinocyte proliferation, and inflammation. Tazarotene also up-regulates three novel genes TIG-1 (tazarotene-induced gene-1), TIG-2, and TIG-3, which may mediate an antiproliferative effect. [4] Tazarotene causes growth suppression in retinoid-responsive breast cancer cell lines by up-regulating TIG3. [5] |
体内活性 | Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in UV-treated Ptch1+/? mice. Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in ionizing radiation-treated Ptch1+/? mice. [5] |
别名 | 他扎罗汀, Tazorac, AGN 190168, Zorac |
分子量 | 351.46 |
分子式 | C21H21NO2S |
CAS No. | 118292-40-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35.2 mg/mL (100 mM)
Ethanol: 17.6 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.8453 mL | 14.2264 mL | 28.4527 mL | 71.1318 mL |
5 mM | 0.5691 mL | 2.8453 mL | 5.6905 mL | 14.2264 mL | |
10 mM | 0.2845 mL | 1.4226 mL | 2.8453 mL | 7.1132 mL | |
20 mM | 0.1423 mL | 0.7113 mL | 1.4226 mL | 3.5566 mL | |
50 mM | 0.0569 mL | 0.2845 mL | 0.5691 mL | 1.4226 mL | |
DMSO | 100 mM | 0.0285 mL | 0.1423 mL | 0.2845 mL | 0.7113 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tazarotene 118292-40-3 Autophagy Metabolism Retinoid Receptor inhibit Inhibitor RAR/RXR Retinoic acid receptors 他扎罗汀 Tazorac AGN-190168 AGN 190168 Zorac AGN190168 Retinoid X receptors inhibitor